PALO ALTO, Calif., March 20, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical firm targeted on growing medicines for genetic circumstances, at the moment introduced that on March 18, 2026, the compensation committee of BridgeBio’s board of administrators accepted fairness grants to 29 new workers in restricted inventory models for an combination of 70,916 shares of the Firm’s frequent inventory. One-fourth of the shares underlying every worker’s restricted inventory models will vest on February 16, 2027, with one-twelfth of the remaining shares underlying every such worker’s restricted inventory models vesting on a quarterly foundation thereafter, in every case, topic to every such worker’s continued employment with the Firm or one among its subsidiaries on such vesting dates.
The above-described awards have been every granted as an inducement materials to the staff getting into into employment with the Firm in accordance with Nasdaq Itemizing Rule 5635(c)(4) and have been granted pursuant to the phrases of the Plan. The Plan was adopted by BridgeBio’s board of administrators in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.
About BridgeBio Pharma, Inc.BridgeBio exists to develop transformative medicines for genetic circumstances. Hundreds of thousands of individuals worldwide residing with genetic circumstances lack therapy choices, actually because drug improvement for small affected person populations will be commercially difficult. We purpose to bridge the hole between developments in genetic science and significant medicines for underserved affected person populations. Our decentralized, hub-and-spoke mannequin is designed for pace, precision, and scalability. Autonomous and empowered groups deal with particular person circumstances, whereas a central hub supplies the scientific, regulatory, and industrial capabilities wanted to deliver innovation to market. For extra info, go to bridgebio.com and comply with us on LinkedIn, X, Fb, Instagram, YouTube, and TikTok.
